XPH(SZ:300147)2022-12-08 03:21Group 1: Company Development Strategy - The company plans to focus on the development of traditional Chinese medicine while implementing a comprehensive strategy in the Chinese medicine resource sector, including full industry chain, full channel, and full category [2][3] - The company aims to actively expand into the cutting-edge biopharmaceutical field [3] Group 2: Clinical Research and Collaborations - The company is collaborating with Hospital 458 on a clinical research project for specific T cell adoptive immunotherapy targeting solid tumors, primarily focusing on liver cancer and non-small cell lung cancer caused by hepatitis B [3] - Phase one of the clinical trial has been completed, and data is currently being organized [3] Group 3: Mergers and Acquisitions - Mergers and acquisitions are considered a pathway for external growth and a strategic direction for the company [3][4] - The management will cautiously evaluate risks and benefits before proceeding with any mergers or acquisitions, focusing on targets that complement the company's products, technology, and channels [4] Group 4: Management Team Collaboration - The company signed an investment cooperation letter with Weng Gexin and his management team on July 10, 2015, to establish a joint venture in Beijing for prescription drug marketing [4] - The project is progressing as planned, with the company committed to timely information disclosure as per relevant regulations [4] Group 5: Financial Performance - The net profit of Bozhou Huqiao Pharmaceutical Co., Ltd. declined in the first half of 2015 due to preparations for a new GMP certification and restrictions on production capacity [4] - The decline in profit was also influenced by relevant national pharmaceutical industry policies [4]